Skin microbiome improving agents and cosmetics for improving skin microbiome

Abstract

To provide a novel agent for improving skin microbiota.SOLUTION: Provided is an agent for improving skin microbiota, comprising enzyme-treated royal jelly as an active ingredient.SELECTED DRAWING: None

Description

Technical Field

[0001] The present invention relates to a skin microbiota improving agent and a cosmetic for improving skin microbiota.

Background Art

[0002] The skin microbiota (also referred to as skin flora or skin commensal bacteria) present on human skin consists of hundreds of types of bacteria, with beneficial bacteria that contribute to health and harmful bacteria involved in diseases coexisting. This coexisting state is generally referred to as the diversity of the skin microbiota. It has been reported that the skin microbiota varies depending on the skin condition. For example, in atopic dermatitis, it is said that the diversity of the skin microbiota decreases and the proportion of Staphylococcus aureus (harmful bacteria) increases.

[0003] Patent Document 1 discloses a skin microbiota improving agent characterized by containing fermented milk whey obtained by fermenting milk with Lactobacillus helveticus.

Prior Art Documents

Patent Documents

[0004]

Patent Document 1

Summary of the Invention

Problems to be Solved by the Invention

[0005] An object of the present invention is to provide a novel skin microbiota improving agent.

Means for Solving the Problems

[0006] The present inventors conducted intensive research to achieve the above object and found that enzymatically treated royal jelly has an excellent effect on improving skin microbiota, leading to the present invention.

[0007] That is, the present invention relates to the following [1] to [7]. [1] A skin microbiome improving agent containing enzyme-treated royal jelly as the active ingredient. [2] A skin microbiota improving agent according to [1], used to reduce the proportion of at least one species selected from the group consisting of Cutibacterium and Staphylococcus species in the skin microbiota. [3] The skin microbiota improving agent described in [2], wherein the above-mentioned Cutibacterium species is Propionibacterium acnes and the above-mentioned Staphylococcus species is Staphylococcus aureus. [4] A skin microbiome improving agent described in any of [1] to [3], used to improve the diversity of the skin microbiome. [5] The above enzyme-treated royal jelly is treated with a peptidase having both endopeptidase activity and exopeptidase activity, the skin microbiota improving agent according to any one of [1] to [4]. [6] A skin microbiome improving agent for external use, as described in any of [1] to [5]. A cosmetic product for improving the skin microbiome, containing a skin microbiome improving agent as described in any of [7][1] to [6]. [Effects of the Invention]

[0008] The present invention provides a novel agent for improving the skin microbiome. [Modes for carrying out the invention]

[0009] The following describes in detail embodiments for carrying out the present invention, but the present invention is not limited to the following embodiments.

[0010] In this specification, "comprise" encompasses both the meanings of "essentially consist of" and "consist of."

[0011] The skin microbiome improving agent of the present invention contains enzyme-treated royal jelly as an active ingredient. By containing enzyme-treated royal jelly as an active ingredient, the skin microbiome improving agent of the present invention can improve the skin microbiome.

[0012] Improving the skin microbiome includes, for example, increasing diversity in the skin microbiome, maintaining or increasing the proportion (occupancy rate) of beneficial bacteria, or decreasing the proportion of harmful bacteria.

[0013] An increase in the diversity of the skin microbiota means an increase in the number of types of bacteria included in the skin microbiota. The diversity of the skin microbiota can be indicated, for example, by the Shannon Diversity Index. The higher the Shannon Diversity Index, the greater the diversity. Furthermore, the higher the Shannon Diversity Index, the greater the number of types and the greater the degree of equality among them.

[0014] The skin microbiome improving agent of the present invention can reduce the proportion of, for example, bacteria of the genus Cutibacterium and Staphylococcus. The genus Cutibacterium may be Propionibacterium acnes. The genus Staphylococcus may be Staphylococcus aureus.

[0015] According to a report by the Japan Allergy Disease Treatment and Guidance Certification Organization, atopic dermatitis patients have low diversity in their skin microbiota and a high proportion of Staphylococcus aureus. The skin microbiota improving agent of the present invention can improve the diversity of the skin microbiota and reduce the proportion of Staphylococcus aureus, and therefore, it is expected that atopic dermatitis can be improved by using the skin microbiota improving agent of the present invention.

[0016] Although acne bacteria are not harmful in themselves, they are known to proliferate depending on the condition of the skin and contribute to the development of acne. Since the skin microbiome improving agent of the present invention can reduce acne bacteria, it is considered that the skin microbiome improving agent of the present invention is effective in preventing or improving acne.

[0017] The skin microbiota improving agent of the present invention can be suitably used for healthy skin (skin without diseases). The skin microbiota improving agent of the present invention may be used, for example, on the skin of a person with atopic dermatitis or the skin of a person with acne.

[0018] The skin microbiota improving agent of the present invention also includes the meaning of an additive that imparts a skin microbiota improving effect.

[0019] Royal jelly is a milky white jelly-like substance made by mixing the secretions secreted from the hypopharyngeal gland and the greater parotid gland of worker bees aged 3 to 12 days old among bees. As the main bioactive components in royal jelly, for example, organic acids such as saturated fatty acids and unsaturated fatty acids peculiar to royal jelly, as well as proteins, amino acids, peptides, lipids, saccharides, vitamin Bs, folic acid, nicotinic acid, pantothenic acid and other vitamins, various minerals and the like can be mentioned. The production area of royal jelly may be any of European countries, Oceanian countries, the United States, Brazil, Japan, China, and other Asian countries, etc.

[0020] Enzyme-treated royal jelly is obtained by treating royal jelly with a proteolytic enzyme (protease). Preferably, it is low-allergen enzyme-treated royal jelly in which an allergic reaction caused by the protein contained in royal jelly is suppressed by protease treatment. Therefore, in addition to the protease degradation products of the proteins contained in royal jelly, enzyme-treated royal jelly may contain organic acids such as the aforementioned saturated fatty acids and unsaturated fatty acids, lipids, saccharides, vitamins, and various minerals.

[0021] The royal jelly used for the production of enzyme-treated royal jelly is not particularly limited, and examples thereof include raw royal jelly, royal jelly powder obtained by drying raw royal jelly into powder, or an extract obtained by extracting raw royal jelly with water or hydrous ethanol or the like.

[0022] The production of enzyme-treated royal jelly can be carried out by treating royal jelly raw materials with an enzyme having at least endopeptidase activity, an enzyme having at least exopeptidase activity, and / or an enzyme having both endopeptidase activity and exopeptidase activity.

[0023] Examples of proteolytic enzymes having at least endopeptidase activity include endopeptidases derived from animals (e.g., trypsin, chymotrypsin, etc.), plants (e.g., papain, etc.), and microorganisms (e.g., lactic acid bacteria, yeast, mold, Bacillus subtilis, actinomycetes, etc.).

[0024] Examples of proteolytic enzymes having at least exopeptidase activity include carboxypeptidase, aminopeptidase, exopeptidases derived from microorganisms (e.g., lactic acid bacteria, Aspergillus spp., Rhizopus spp., etc.), pancreatin having endopeptidase activity as well, pepsin, and the like.

[0025] Among these various enzymes, preferred examples of enzymes possessing both exopeptidase and endopeptidase activity include Streptomyces griseus-produced peptidase (product name: Actinase AS), Aspergillus oryzae-produced peptidase (product names: Protease A, Flavorzyme, Proteax), and Aspergillus melleus-produced peptidase (product name: Protease P). Preferred examples of enzymes possessing exoprotease activity include Aspergillus oryzae-produced peptidase (product names: Umamizyme G, Promod 192P, Promod 194P, Sumizyme FLAP), and Aspergillus sojae-produced peptidase (product name: Sternzyme). Examples include peptidases produced by Aspergillus species (product name: Cocrase P) and peptidases produced by Rhizopus oryzae (product name: Peptidase R). Furthermore, preferred examples of enzymes possessing endoprotease activity include peptidase produced by Bacillus subtilis (trade names: Orientase 22BF, Nucleicin), peptidase produced by Bacillus licheniformis (trade name: Alcalase), peptidase produced by Bacillus stearothermophilus (trade name: Protease S), peptidase produced by Bacillus amyloliquefaciens (trade name: Neutralase), and peptidase produced by Bacillus species (trade name: Protamex).

[0026] Enzymatic treatment to reduce the allergenicity of royal jelly can be carried out, for example, in accordance with the descriptions in Japanese Patent Publication No. 2007-295919 and Japanese Patent Publication No. 2007-295920.

[0027] Enzyme-treated royal jelly may also be a filtrate obtained by filtering the enzyme-treated royal jelly solution. Filtration can be performed, for example, by suction filtration with a particle pore size of less than 10 μm or by a filter press.

[0028] Commercially available enzyme-treated royal jelly may be used. Specific examples of commercially available enzyme-treated royal jelly include, for example, Enzyme-Decomposed Royal Jelly King (manufactured by Yamada Bee Farm Co., Ltd.).

[0029] The amount of the active ingredient in the skin microbiome improving agent of the present invention may be, for example, 0.1% by mass or more, 1% by mass or more, 3% by mass or more, 3.5% by mass or more, 5% by mass or more, 7% by mass or more, 10% by mass or more, 15% by mass or more, 20% by mass or more, 25% by mass or more, 30% by mass or more, 35% by mass or more, 40% by mass or more, 45% by mass or more, 50% by mass or more, 55% by mass or more, 60% by mass or more, 65% by mass or more, 70% by mass or more, 75% by mass or more, 80% by mass or more, 85% by mass or more, 90% by mass or more, 93% by mass or more, 95% by mass or more, 98% by mass or more, 99% by mass or more, or 100% by mass, relative to the total amount of the skin microbiome improving agent. The content of the above active ingredient in the skin flora improving agent is solid content based on the total amount of the skin flora improving agent, for example, 100% by mass or less, 99% by mass or less, 98% by mass or less, 95% by mass or less, 93% by mass or less, 90% by mass or less, 85% by mass or less, 80% by mass or less, 75% by mass or less, 70% by mass or less, 65 It may be less than or equal to 60 mass%, 55 mass% or less, 50 mass% or less, 45 mass% or less, 40 mass% or less, 35 mass% or less, 30 mass% or less, 25 mass% or less, 20 mass% or less, 15 mass% or less, 10 mass% or less, 8 mass% or less, 5 mass% or less, 3 mass% or less, or 1 mass% or less.

[0030] The skin microbiome improving agent of the present invention can be used topically. The amount of the skin microbiome improving agent of the present invention administered to the skin may vary depending on the site and scope of application, but for example, the amount applied to the skin may be 0.01 mg to 50 mg of the active ingredient in terms of dry solid content, preferably 0.02 mg to 40 mg of the active ingredient, and may be 0.02 mg to 35 mg, or 0.025 mg to 30 mg of the active ingredient.

[0031] The skin microbiome improving agent of the present invention can be used as an ingredient in cosmetics. Cosmetics containing the skin microbiome improving agent of the present invention as an ingredient can be considered cosmetics for improving the skin microbiome. The cosmetics of the present invention also include quasi-drugs. The amount of the above-mentioned active ingredient in cosmetics containing the skin microbiome improving agent of the present invention is not particularly limited, and any effective amount that can achieve the parenteral administration dose of the agent is sufficient.

[0032] Cosmetics containing the skin microbiome improving agent of the present invention as one component can be manufactured, for example, by adding the skin microbiome improving agent of the present invention to an intermediate product in the manufacturing process of cosmetics.

[0033] The pH of the skin microbiome improving agent of the present invention, or the cosmetic containing the skin microbiome improving agent, may be, for example, 4.5 to 6.5, or 5.0 to 6.5.

[0034] Cosmetics may be in any form, such as solid, liquid, or paste. Cosmetics may be medicated cosmetics (i.e., quasi-drugs). Cosmetics include all cosmetics that can be applied to parts of animals (including humans), such as skin, mucous membranes, body hair, hair, scalp, nails, teeth, facial skin, and lips.

[0035] Cosmetic formulations can take a wide range of forms, including aqueous solutions, solubilized solutions, emulsified solutions, powders, oil-based solutions, gels, ointments, aerosols, two-layer water-oil systems, and three-layer water-oil-powder systems.

[0036] The uses of cosmetics are arbitrary. For example, basic cosmetics include facial cleansers, toners, lotions, creams, gels, essences, serums, packs, masks, mists, and UV protection cosmetics. Makeup cosmetics include foundations, lipsticks, blushes, eyeshadows, eyeliners, and mascaras. Nail cosmetics include nail polish, base coats, top coats, and nail polish removers. Other products include facial cleansers, (paste or liquid) toothpaste, mouthwash, oral cosmetics, massage agents, cleansing agents, aftershave lotions, pre-shave lotions, shaving creams, body soaps, soaps, shampoos, conditioners, hair treatments, hair styling products, hair tonics, hair mists, hair foams, hair liquids, hair gels, hair sprays, hand creams, hand soaps, hair growth products, antiperspirants, and bath additives.

[0037] In addition to the enzyme-treated royal jelly mentioned above, the above-mentioned cosmetics may contain, as needed, other ingredients commonly used in cosmetics, such as alcohol, disinfectants, preservatives, surfactants, alcohols, aqueous components, water, colorants, pH adjusters, solubilizers, abrasives, foaming agents, enzymes, flavoring agents, chelating agents, excipients, thickeners, bases, emulsifiers, solvents, stabilizers, oils, cleaning agents (lactic acid bacteria), whitening agents, moisturizers, antioxidants, UV absorbers, powder components, colorants, various skin nutrients, etc.

[0038] The alcohol may be, for example, 1,3-butylene glycol, pentylene glycol, or phenoxyethanol. The total alcohol content in the cosmetic may be, for example, 5% or more by weight, 7% or more by weight, 10% or more by weight, 12% or more by weight, 20% or less by weight, 18% or less by weight, or 15% or less by weight, relative to the total amount of the cosmetic.

[0039] The oily agent may be, for example, caprylic / capric triglyceride. The amount of oily agent in the cosmetic product may be, for example, 0.5% or more by weight, 0.8% or more by weight, 1.0% or more by weight, 1.3% or more by weight, 5% or less by weight, 3% or less by weight, or 2% or less by weight, relative to the total amount of the cosmetic product.

[0040] The thickening agent may be, for example, a hydrophilic thickening agent. Examples of thickening agents include carbomer, etc. The amount of thickening agent in the cosmetic product may be, for example, 0.05% or more by weight, 0.1% or more by weight, 0.15% or more by weight, 0.2% or more by weight, 3% or less by weight, 1% or less by weight, 0.5% or less by weight, or 0.3% or less by weight, relative to the total amount of the cosmetic product.

[0041] The cosmetic product comprising the dermal thickness improving agent and skin texture improving agent of the present invention may further contain (acrylates / alkyl acrylate (C10-30)) crosspolymer. These are cosmetic ingredients known as thickeners and emulsifying stabilizers, and are preferred because they have the effect of promoting the penetration of royal jelly into the skin.

[0042] (Acrylates / C10-30 alkyl acrylate) crosspolymer is a copolymer of one or more monomers consisting of acrylic acid, methacrylic acid, or simple esters thereof, and alkyl acrylate, crosslinked with sucrose allyl ether or pentaerythritol allyl ether. Here, alkyl acrylate is specifically an alkyl acrylate having 10 to 30 carbon atoms. As the (Acrylates / C10-30 alkyl acrylate) crosspolymer, a commercially available (Acrylates / C10-30 alkyl acrylate) crosspolymer (e.g., Pemulen® TR-1) may be used.

[0043] The content of (acrylates / alkyl acrylate (C10-30)) crosspolymer in cosmetics may be, for example, 0.01% by mass or more, 0.1% by mass or more, 0.3% by mass or more, 0.4% by mass or more, 0.5% by mass or more, 1% by mass or more, 2% by mass or more, 3% by mass or more, 5% by mass or more, and 20% by mass or less, 15% by mass or less, 10% by mass or less, 8% by mass or less, 5% by mass or less, 3% by mass or less, 2% by mass or less, 1% by mass or less, or 0.5% by mass or less, based on the total amount of cosmetics.

[0044] The skin microbiome improving agent of the present invention described above is applicable to mammals, including humans (preferably humans). [Examples]

[0045] The present disclosure will be described in more detail below with reference to examples. However, the present invention is not limited to these examples.

[0046] [Preparation of enzyme-treated royal jelly extract] Enzymatic treatment of royal jelly was performed according to the method described in WO2020 / 196065A1. Specifically, 474 g of raw royal jelly was mixed with 400 mL of deionized water and stirred until homogeneous to prepare a royal jelly dilution. The pH of the royal jelly dilution was adjusted to 7.8 by adding 2N NaOH aqueous solution. Next, a solution of 4.75 g of Proteax (Amano Enzyme Co., Ltd.), which has both endopeptidase and exopeptidase activity, dissolved in 20 mL of deionized water was added to the royal jelly dilution, and then more deionized water was added until the total volume reached 980 g. The reaction mixture was stirred with a propeller and reacted at 50°C (constant temperature water bath) for 2 hours to perform hydrolysis. The temperature of the constant temperature water bath was raised to 80°C and stirred for 15 minutes to inactivate the protease. The obtained enzyme-treated royal jelly solution was filtered to a particle pore size of 3 μm by suction filtration or filter press to obtain an enzyme-treated royal jelly filtrate. Butylene glycol, pentylene glycol, phenoxyethanol, and purified water were added to the enzyme-treated royal jelly filtrate to a concentration of 2.5% by weight to obtain an enzyme-treated royal jelly extract.

[0047] [Preparation of test samples] Cosmetic products containing enzyme-treated royal jelly extract (hereinafter referred to as RJ Cream) and placebo cosmetics (hereinafter referred to as Placebo) were prepared according to the formulations shown in Table 1. The units of the values ​​are in weight percent. 1,3-butylene glycol, pentylene glycol, and phenoxyethanol are contained in the enzyme-treated royal jelly extract at the same concentrations as in the placebo.

[0048] [Table 1]

[0049] Forty-eight women aged 45-60 (average age 53.3 years) were instructed to apply either RJ Cream or a placebo to one half of their face twice daily for 12 weeks. The other test product was applied to the other half of their face under the same conditions. The effects of RJ Cream on the skin were examined by comparing the results to the placebo-treated side.

[0050] [Statistical analysis] Statistical analysis was performed on each evaluation item using the following methods. The significance level was set at 5% using a two-tailed test. For evaluation items with missing data, all observation points for the relevant subjects were treated as missing values.

[0051] (intragroup comparison) For each evaluation item, the pre-use control group was used, and the post-use group was tested using either a paired t-test or a Wilcoxon signed-rank test. The significance level was adjusted according to the number of tests performed using the Bonferroni method.

[0052] (Comparison between groups) For each evaluation item, the side treated with placebo in the same subject was used as the control, and Student's t-test was performed on the side treated with RJ.

[0053] [Application of test sample] Approximately 1g of the test product was taken and applied to half of the face twice a day (morning and evening) for 12 weeks. If participants normally use lotion or cream, they were instructed to use the test product instead. The order of application for skincare cosmetics and the method of application for the test product were as follows. (1) Everyday toner (2) Everyday essences, serums, etc. (3) Test sample Take about half the amount, approximately 0.6g (3 pumps), into your dry palm and gently and carefully apply it to half of your face, spreading it evenly. Next, take the remaining half, approximately 0.4g (2 pumps), into your palm and gently and carefully apply it to the other half of your face, then gently and carefully apply it to the corners of your eyes as well, and finally, cup your hands over your face to help it absorb into the skin.

[0054] For skin microbiota, samples were collected upon arrival at the testing site (before washing the face).

[0055] [Bacteria flora analysis] Commensal bacteria were collected from the cheeks using the S-KIN kit (swabs soaked in physiological saline) from World Fusion Co., Ltd., and S-KIN skin flora analysis was performed. The bacterial species constituting the skin microbiota were identified by 16S rRNA metagenomic analysis. The calculated occupancy rate of each bacterium and the Shannon diversity index are shown in Table 2.

[0056] [Table 2]

[0057] The use of a test product containing enzyme-treated royal jelly extract was confirmed to reduce the amount of Propionibacterium acnes and Staphylococcus aureus in the skin microbiota, and to improve its diversity.

Claims

1. An enzyme-treated royal jelly that improves the skin's bacterial flora.

2. A skin microbiota improving agent according to claim 1, used to reduce the proportion of at least one species selected from the group consisting of Cutibacterium and Staphylococcus species in the skin microbiota.

3. The skin microbiota improving agent according to claim 2, wherein the Cutibacterium species is Propionibacterium acnes and the Staphylococcus species is Staphylococcus aureus.

4. A skin microbiota improving agent according to claim 1 or 2, used to improve the diversity of the skin microbiota.

5. The skin microbiota improving agent according to claim 1 or 2, wherein the enzyme-treated royal jelly is treated with a peptidase having endo-peptidase activity and exopeptidase activity.

6. A skin bacterial flora improving agent according to claim 1 or 2, for external use on the skin.

Images